Adam Ametovski

10 years experience in synthetic organic chemistry with a focus on reaction development, total synthesis and medicinal chemistry.  PhD studies focused reaction development using organocatalysts to enable the synthesis of complex natural products.  Postdoctoral studies involved the development of  small molecule therapeutics for the treatment of Dravet syndrome and related forms of epilepsy. This included medicinal and computation chemistry around cannabidiol and a range of related natural products. 

 10 years’ experience in organic synthesis, including reaction discovery (2 years), total synthesis (2 years) and medicinal chemistry (4 years). Specifically, this research has enabled the development of new enantioselective organocatalytic methods aimed at the synthesis of complex natural products such as the important cannabinoid, delta-9-tetrahydrocannbinol. More recently, his work has focused on the design, synthesis, and purification of phyto- and synthetic-cannabinoid analogues for the in vitro and in vivo exploration of cannabinoid receptor activity as well as for their screening as potential drugs in disease models such as Dravet syndrome and related epilepsies. This also included utilization of computational chemistry to rationalise observed results. Notably, 2 years experience as medicinal chemistry team leader which involved directing/overseeing research programs with a team of 3 PhD students.

2015-2019 PhD in Synthetic Organic Chemistry (reaction development and total sysnthesis), Monash University, Australia

2011-2014 Bachelor of Science with Honours (1st Class), Monash University Australia

Majors: Chemistry, Geology 

2004-2010 High School Graduate, Cranbourne Secondary College, Melbourne, Australia